Posted by Michael Wonder on 09 Sep 2020
PHARMAC opens consultation to address New Zealand’s biggest health issue
9 September 2020 - Proposal to list type 2 diabetes medicine Jardiance.
Boehringer Ingelheim New Zealand welcomes a major PHARMAC proposal which could see up to 50,000 New Zealanders with type 2 diabetes mellitus and high risk of heart and kidney complications receive funded access to a medicine that not only lowers blood sugar, but also reduces the risk of dying from heart complications.
Under the new proposal, from 1 December 2020, Jardiance (empagliflozin) would become the first and only oral diabetes medicine on New Zealand’s Pharmaceutical Schedule2 proven to deliver a benefit beyond blood glucose-lowering in people with type 2 diabetes and established cardiovascular (heart and stroke) disease.
